Download the full-sized PDF
Permanent link (DOI): https://doi.org/10.7939/R36970B5C
This file is in the following communities:
|Agricultural, Food and Nutritional Science, Department of|
This file is in the following collections:
|Journal Articles (Agricultural, Food and Nutritional Science)|
Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: Selumetinib in patients with cholangiocarcinoma Open Access
- Author or creator
Prado, Carla M.
Doyle, L. Austin
Baracos, Vickie E.
Sawyer, Michael B.
- Additional contributors
- Type of item
- Journal Article (Published)
background: Cancer cachexia is characterised by skeletal muscle wasting; however, potential for muscle anabolism in patients with advanced cancer is unproven. methods: Quantitative analysis of computed tomography images for loss/gain of muscle in cholangiocarcinoma patients receiving selumetinib (AZD6244; ARRY-142886) in a Phase II study, compared with a separate standard therapy group. Selumetinib is an inhibitor of mitogen-activated protein/extracellular signal–regulated kinase and of interleukin-6 secretion, a putative mediator of muscle wasting. results: Overall, 84.2% of patients gained muscle after initiating selumetinib; mean overall gain of total lumbar muscle cross-sectional area was 13.6 cm2/100 days (~2.3 kg on a whole-body basis). Cholangiocarcinoma patients who began standard treatment were markedly catabolic, with overall muscle loss of −7.3 cm2/100 days (~1.2 kg) and by contrast only 16.7% of these patients gained muscle. conclusion: Our findings suggest that selumetinib promotes muscle gain in patients with cholangiocarcinoma. Specific mechanisms and relevance for cachexia therapy remain to be investigated.
- Date created
- License information
- © 2012 Cancer Research UK, distributed under an Attribution-NonCommerical-ShareALike 4.0 International
- Citation for previous publication
Prado, C. M., Bekaii-Saab, T., Doyle, L. A., Shrestha, S., Ghosh, S., Baracos, V. E., & Sawyer, M. B. (2012). Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: Selumetinib in patients with cholangiocarcinoma. British Journal of Cancer, 106(10), 1583-1586. http://dx.doi.org/10.1038/bjc.2012.144
- Link to related item
- Date Uploaded
- Date Modified
- Audit Status
- Audits have not yet been run on this file.
File format: pdf (Portable Document Format)
Mime type: application/pdf
File size: 264196
Last modified: 2017:09:06 16:03:10-06:00
Original checksum: 8219ebb3dc5fbc6ad4533b86895d59c9
Copyright note: © 2012 Nature Publishing Group
Well formed: true
File title: title_link
File title: Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma
File author: C M M Prado
Page count: 4